Superluminal Medicines
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $153M
Overview
A preclinical biotech using structure-based design to develop small molecule drugs for neurological disorders.
NeurosciencePsychiatry
Technology Platform
An integrated platform utilizing cryo-EM and computational modeling for structure-based design of small molecules targeting complex neural proteins.
Funding History
2Total raised:$153M
Series A$120M
PIPE$33M
Opportunities
Potential to generate first-in-class assets for major neurodegenerative diseases, attracting significant partnership interest from large pharma.
Risk Factors
High scientific and clinical risk associated with novel CNS targets and the difficulty of demonstrating efficacy in neurological clinical trials.
Competitive Landscape
Enters a high-risk, high-reward neuroscience field crowded with many early-stage biotechs also applying structural biology to CNS drug discovery.